Kylo-12

Phase 1Small molecule

KKylonova (Xiamen) Biopharma co., LTD.

Kylo-12 is one of 16 small molecule programs targeting Hypertriglyceridemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertriglyceridemiaActive, not recruiting

HypertriglyceridemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Cipro

Lopid

Selzentry

Crestor

Zocor

Topamax

Tryngolza (autoinjector)

Ionis Pharmaceuticals

Phase 3

3 8

Redemplo

Arrowhead Pharmaceuticals

Phase 3

3 9

Avandia

Jazz Pharmaceuticals

Preclinical

1 10

Repatha

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

Active, not recruiting·KKylonova (Xiamen) Biopharma co., LTD.·Phase 1·NCT06783881·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Kylo-12. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kylo-12 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kylo-12. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kylonova (Xiamen) Biopharma co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: KKylonova (Xiamen) Biopharma co., LTD.

Kylo-12

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News